MedTrace Logo

The Effect of Sugammadex Versus Neostigmine During Neuromuscular Blockade Reversal

NCT03579589 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-08-11

No results posted yet for this study

Summary

Patients who undergo surgery receive drugs called neuromuscular blocking agents (NMBA) that to block the activity of muscles. When the surgery is over, the block needs to be reversed. Suggammadex and neostigmine are examples of drugs that reverse blocks. This study aims to investigate if sugammadex is associated with a significantly reduced time to discharge from the operating room to the postoperative unit when compared to neostigmine.

Conditions

  • Neuromuscular Blockade

Interventions

DRUG

Sugammadex vs Neostigmine

Patients will be randomized into either Sugammadex or Neostigmine neuromuscular blockade reversal.

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Principal Investigators

  • Sergio D Bergese, MD · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-15
Primary Completion
2019-12-15
Completion
2019-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03579589 on ClinicalTrials.gov